Glenn D. Flux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Glenn D. Flux has a total of 497 co-authors. Here are the top co-authors by number of shared publications:
- Michael Lassmann
Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany
16 shared publications - Manuel Bardiès
Institut de Recherche en Cancérologie de Montpellier, Équipe Labellisée Ligue Contre le Cancer, INSERM U1194, Institut Régional du Cancer de Montpellier, Université de Montpellier, Montpellier, France
14 shared publications - Carlo Chiesa
Nuclear Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
13 shared publications Iain Murray
Joint Department of Physics, The Royal Marsden NHSFT and Institute of Cancer Research, Sutton, United Kingdom
10 shared publications- Jan Taprogge
Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom
10 shared publications Sarah J. Chittenden
Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom; The Institute of Cancer Research, London, United Kingdom
10 shared publications
Latest Publications
- Open Access
- 16 December 2025
- Published by Elsevier in Clinical Oncology
- Vol. 51, 104003
Clinical Trials in Molecular Radiotherapy: An Overview of the Landscape
- 16 December 2025
- Published by Elsevier in Clinical Oncology
- Vol. 51, 104003
Open AccessClinical Trials in Molecular Radiotherapy: An Overview of the Landscape
- 23 July 2025
- Published by Elsevier in Physica Medica
- Vol. 136, 105058
Design and manufacture of a radioactive 3D printed phantom for PET quality control
- 23 July 2025
- Published by Elsevier in Physica Medica
- Vol. 136, 105058
Design and manufacture of a radioactive 3D printed phantom for PET quality control
- Open Access
- 18 June 2025
- Published by Bioscientifica in European Thyroid Journal
- Vol. 14 (4)
Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer
Objective: Serum thyroglobulin measurements are used in the long-term management of patients with differentiated thyroid cancer following thyroidectomy and radioiodine therapy. The use of predictive biomarkers, such as post-operative stimulated thyroglobulin levels and absorbed dose, may help to identify patients at risk of disease recurrence or an unsuccessful initial treatment. Methods: Differentiated thyroid cancer patients treated with 1.1 or 3.7 GBq of radioiodine using recombinant human thyrotropin stimulation or thyroid hormone withdrawal were recruited into observational clinical studies in France, Germany and the UK with aligned study endpoints (MEDIRAD). The maximum absorbed dose to the thyroid remnant was determined and compared to post-operative stimulated thyroglobulin with respect to its ability to predict ablation success. Radioiodine therapy success was defined as unstimulated or stimulated thyroglobulin level of <0.2 or <1.0 ng/mL 9–12 months post-radioiodine. Results: Ninety-four patients had follow-up data and negative antithyroglobulin antibody tests. Seventy-eight patients (83%) were deemed excellent biochemical responders. Post-operative thyroglobulin and maximum absorbed dose predicted ablation success with receiver operating characteristic area under the curves of 0.83 ± 0.05 (P < 0.001) and 0.64 ± 0.08 (P = 0.12). A dose–response relationship between maximum absorbed dose and ablation success was found for patients with a post-operative stimulated thyroglobulin of ≥1 ng/mL. Conclusions: Predictions of ablation success using post-operative stimulated thyroglobulin or the absorbed dose to the thyroid remnant could inform personalisation of management of differentiated thyroid cancer and identify patients where further treatments or more intensive follow-up are required. Patients with a post-operative stimulated Tg of <1 ng/mL likely do not benefit from radioiodine.
- 18 June 2025
- Published by Bioscientifica in European Thyroid Journal
- Vol. 14 (4)
Open AccessPredictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer
Objective: Serum thyroglobulin measurements are used in the long-term management of patients with differentiated thyroid cancer following thyroidectomy and radioiodine therapy. The use of predictive biomarkers, such as post-operative stimulated thyroglobulin levels and absorbed dose, may help to identify patients at risk of disease recurrence or an unsuccessful initial treatment. Methods: Differentiated thyroid cancer patients treated with 1.1 or 3.7 GBq of radioiodine using recombinant human thyrotropin stimulation or thyroid hormone withdrawal were recruited into observational clinical studies in France, Germany and the UK with aligned study endpoints (MEDIRAD). The maximum absorbed dose to the thyroid remnant was determined and compared to post-operative stimulated thyroglobulin with respect to its ability to predict ablation success. Radioiodine therapy success was defined as unstimulated or stimulated thyroglobulin level of <0.2 or <1.0 ng/mL 9–12 months post-radioiodine. Results: Ninety-four patients had follow-up data and negative antithyroglobulin antibody tests. Seventy-eight patients (83%) were deemed excellent biochemical responders. Post-operative thyroglobulin and maximum absorbed dose predicted ablation success with receiver operating characteristic area under the curves of 0.83 ± 0.05 (P < 0.001) and 0.64 ± 0.08 (P = 0.12). A dose–response relationship between maximum absorbed dose and ablation success was found for patients with a post-operative stimulated thyroglobulin of ≥1 ng/mL. Conclusions: Predictions of ablation success using post-operative stimulated thyroglobulin or the absorbed dose to the thyroid remnant could inform personalisation of management of differentiated thyroid cancer and identify patients where further treatments or more intensive follow-up are required. Patients with a post-operative stimulated Tg of <1 ng/mL likely do not benefit from radioiodine.
- Open Access
- 19 May 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (11) , 115001
A validation protocol for 177Lu-SPECT image quantification as a basis for multi-centre kidney dosimetry
Objective. Multicentre studies in molecular radiotherapy face challenges in ensuring the comparability of dosimetry results. The aim of this study was to develop a validation protocol to achieve equivalent 177Lu-SPECT quantification across centres, consisting of a test exercise in combination with an action level. Approach. 177Lu-SPECT/CT imaging of 3D-printed kidney phantoms with non-uniform activity distributions was conducted at five hospitals in Sweden and the UK. In total, 12 quantification systems (QSs) were included, where a QS was defined as the combination of a given camera system, reconstruction method and image-analysis method. The accuracy of image-based estimates of the activity concentration was investigated for three approaches to multicentre dosimetry: one site-specific, and two variants of centralised approaches. For the site-specific approach, the reference value was blinded to the evaluating operators. Prior to the evaluation, the participants agreed on an action level, specified as an obtained deviation larger than ±10% from the reference value. Sites responsible for a QS that yielded larger deviations, and therefore did not comply, were required to present an action plan, i.e., a plan for further method optimisation. Main results. For the site-specific approach, deviations larger than 10% were obtained for six out of 12 QS (range −11% to +27%). Action plans were presented for these QS and was implemented by one site (two QS). For the two variants of centralised approaches, where nine QS were included in total, deviations of within 10% were obtained for nine and seven QS, respectively. Significance. A quantification test combined with an action level can serve as an initial validation to enable further development and to achieve equivalent 177Lu-SPECT quantification across sites.
- 19 May 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (11) , 115001
Open AccessA validation protocol for 177Lu-SPECT image quantification as a basis for multi-centre kidney dosimetry
Objective. Multicentre studies in molecular radiotherapy face challenges in ensuring the comparability of dosimetry results. The aim of this study was to develop a validation protocol to achieve equivalent 177Lu-SPECT quantification across centres, consisting of a test exercise in combination with an action level. Approach. 177Lu-SPECT/CT imaging of 3D-printed kidney phantoms with non-uniform activity distributions was conducted at five hospitals in Sweden and the UK. In total, 12 quantification systems (QSs) were included, where a QS was defined as the combination of a given camera system, reconstruction method and image-analysis method. The accuracy of image-based estimates of the activity concentration was investigated for three approaches to multicentre dosimetry: one site-specific, and two variants of centralised approaches. For the site-specific approach, the reference value was blinded to the evaluating operators. Prior to the evaluation, the participants agreed on an action level, specified as an obtained deviation larger than ±10% from the reference value. Sites responsible for a QS that yielded larger deviations, and therefore did not comply, were required to present an action plan, i.e., a plan for further method optimisation. Main results. For the site-specific approach, deviations larger than 10% were obtained for six out of 12 QS (range −11% to +27%). Action plans were presented for these QS and was implemented by one site (two QS). For the two variants of centralised approaches, where nine QS were included in total, deviations of within 10% were obtained for nine and seven QS, respectively. Significance. A quantification test combined with an action level can serve as an initial validation to enable further development and to achieve equivalent 177Lu-SPECT quantification across sites.
- 15 June 2024
- Published by Elsevier in Physica Medica
- Vol. 124, 103413
Physics for molecular radiotherapy – The battle between science and simplicity
- 15 June 2024
- Published by Elsevier in Physica Medica
- Vol. 124, 103413
Physics for molecular radiotherapy – The battle between science and simplicity
- 17 March 2024
- Published by Elsevier in Physica Medica
- Vol. 120, 103328
Symposium on molecular radiotherapy dosimetry: The first of a series?
- 17 March 2024
- Published by Elsevier in Physica Medica
- Vol. 120, 103328
Symposium on molecular radiotherapy dosimetry: The first of a series?
- Open Access
- 4 November 2023
- Published by Elsevier in Physica Medica
- Vol. 116, 103166
EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy – Molecular radiotherapy
- 4 November 2023
- Published by Elsevier in Physica Medica
- Vol. 116, 103166
Open AccessEFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy – Molecular radiotherapy
- 1 September 2023
- Published by SAGE Publications in Thyroid®
- Vol. 33 (9) , 1119-1123
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy
- 1 September 2023
- Published by SAGE Publications in Thyroid®
- Vol. 33 (9) , 1119-1123
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy
- 1 January 2023
- Published by Springer Nature
- p. 123-132
Radioiodine Dosimetric Approaches: Current Concepts and Future Directions
- 1 January 2023
- Published by Springer Nature
- p. 123-132
Radioiodine Dosimetric Approaches: Current Concepts and Future Directions
- 29 December 2022
- Published by Radiation Research Society in Radiation Research
- Vol. 199 (2) , 202-210
Leonidas D. Marinelli: Cold War Scientist
- 29 December 2022
- Published by Radiation Research Society in Radiation Research
- Vol. 199 (2) , 202-210
Leonidas D. Marinelli: Cold War Scientist